Compound A12 Cuts Sepsis Inflammation in Mice

The 100-fold more potent plant-derived molecule is research-stage and has not yet been tested in humans.

Updated on Nov. 5, 2026 in Life Sciences

Compound A12 Cuts Sepsis Inflammation in Mice

Researchers report a new compound, A12, that reduced sepsis-associated inflammation in mouse models. A12 is a covalent inhibitor derived from tanshinone IIA, a compound found in Salvia miltiorrhiza. The work is research-stage: it has been tested in cells and mice, not in humans, and is not an available treatment.

Why it matters

Excessive inflammation contributes to organ injury in sepsis, so compounds that dampen the inflammatory response are a focus of drug development. The study shows a route for turning a natural product into a more potent, targeted agent by adding a chemical group that bonds to a specific protein.

In mice given A12 orally, levels of TNF-α, IL-6, and IL-12 fell in a lipopolysaccharide-induced model, and A12 extended survival in a cecal ligation and puncture sepsis model compared with its parent compound's baseline anti-inflammatory activity. Cell results were reported at submicromolar concentrations, but human dosing and toxicity data are not part of this study.

The players

Acta Pharmaceutica Sinica B

A peer-reviewed journal that published the study describing A12 and its target DNAJC9.

The details

A12 was built by modifying tanshinone IIA, adding a chemical group designed to form a covalent bond with a target protein, which means it binds permanently rather than briefly. Screening and structural optimization identified A12 as the lead compound. The target is DNAJC9, a co-chaperone (a helper protein that assists heat shock proteins in folding other proteins), and A12 bonds to its cysteine 243 residue. Reducing DNAJC9 expression suppressed inflammatory cytokines and diminished the extra effect of A12, linking DNAJC9 modulation to nuclear accumulation of HSP70 and suppression of NF-κB, a central inflammatory signaling pathway.

Timeline

  1. June 2026: the journal article's DOI was registered in Acta Pharmaceutica Sinica B, volume 16, issue 10.

  2. November 5, 2026: News-Medical published coverage of the study.

The Tech Race

The work sits in the effort to find sepsis drugs that act on the inflammatory response rather than the infection alone. Its covalent-inhibitor approach, which permanently binds a specific protein, is a design strategy that competing drug-discovery programs also pursue.

This is research-stage work, so no patient can access A12 yet. Any path to clinical use would require human safety and efficacy trials that have not been announced.

The takeaway

The key insight is that adding a covalent bond to a natural product can raise its potency sharply, here about 100-fold. Watch for whether follow-up work moves A12 into human safety testing, which has not been announced.

Further reading

For broader context on how drug candidates move from lab studies to clinical use, explore Life Sciences coverage on We are the Frontier.

More information

Read the peer-reviewed Acta Pharmaceutica Sinica B journal article for the full methods and data.

Source note: This article includes information reported by News-Medical.